Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The structural basis for substrate and inhibitor selectivity of the anthrax lethal factor.

Benjamin E Turk1, Thiang Yian Wong, Robert Schwarzenbacher

  • 1Division of Signal Transduction, Department of Medicine, Beth Israel Deaconess Medical Center, and Harvard Medical School, 330 Brookline Avenue, Boston, Massachusetts 02215, USA.

Nature Structural & Molecular Biology
|January 14, 2004
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Baseline cellular state dictates the molecular impact of <i>KRAS</i> mutant variants in pancreatic cancer cells.

bioRxiv : the preprint server for biology·2026
Same author

Cancer hotspot mutations rewire ERK2 specificity by selective exclusion of docking interactions.

The Journal of biological chemistry·2025
Same author

Setdb1 Loss Induces Type I Interferons and Immune Clearance of Melanoma.

Cancer immunology research·2024
Same author

Aurora B controls anaphase onset and error-free chromosome segregation in trypanosomes.

The Journal of cell biology·2024
Same author

Protein phosphatase 6 activates NF-κB to confer sensitivity to MAPK pathway inhibitors in <i>KRAS</i>- and <i>BRAF</i>-mutant cancer cells.

Science signaling·2024
Same author

The intrinsic substrate specificity of the human tyrosine kinome.

Nature·2024

Researchers developed novel peptide inhibitors targeting anthrax lethal factor (LF), a key enzyme in anthrax pathogenesis. These inhibitors show promise for new anthrax therapeutics by blocking LF activity and protecting cells.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Pathogen Research

Background:

  • Anthrax poses a significant biodefense threat, necessitating novel therapeutic strategies.
  • Anthrax lethal factor (LF) is a metalloproteinase crucial to anthrax pathogenesis.

Purpose of the Study:

  • To rapidly identify optimal peptide substrates for anthrax lethal factor (LF).
  • To develop effective peptide-based inhibitors for LF.

Main Methods:

  • Utilized a mixture-based peptide library approach for substrate identification.
  • Employed enzyme inhibition assays and cell-based cytolysis protection assays.
  • Determined crystal structures of LF bound to peptide substrates and inhibitors.

Main Results:

Related Experiment Videos

  • Identified potent peptide analogs that inhibit LF enzyme activity in vitro.
  • Demonstrated protection of cultured macrophages from LF-mediated cytolysis.
  • Obtained crystal structures providing insights into LF-peptide interactions.

Conclusions:

  • The peptide library approach is effective for rapid identification of LF substrates and inhibitors.
  • Identified peptide inhibitors offer a promising foundation for developing new anthrax therapeutics.
  • Structural data can guide the design of next-generation LF inhibitors for improved efficacy and selectivity.